{{Expert-subject|Medicine|date=February 2009}}
{{Infobox disease
 | Name           = Evans syndrome
 | Image          = 
 | Caption        = 
 | DiseasesDB     = 29724
 | ICD10          = {{ICD10|D|69|3|d|65}}
 | ICD9           = {{ICD9|287.32}}
 | ICDO           = 
 | OMIM           = 
 | MedlinePlus    = 
 | eMedicineSubj  = ped
 | eMedicineTopic = 721
 | MeshID         = 
}}

'''Evans syndrome''' is an [[autoimmune disease]] in which an individual's [[antibodies]] attack their own [[red blood cell]]s and [[platelet]]s.<ref name="pmid14782741">{{cite journal |author=Evans RS, Takahashi K, Duane RT, Payne R, Liu C |title=Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology |journal=A.M.AARRAYrchives of internal medicine |volume=87 |issue=1 |pages=48–65 |year=1951 |pmid=14782741 |doi=}}</ref> Both of these events may occur simultaneously or one may follow on from the other.<ref name="pmid16398647">{{cite journal |author=Norton A, Roberts I |title=Management of Evans syndrome |journal=Br. J. Haematol. |volume=132 |issue=2 |pages=125–37 |year=2006 |pmid=16398647 |doi=10.1111/j.1365-2141.2005.05809.x}}</ref>

Its overall pathology resembles a combination of [[autoimmune hemolytic anemia]] and [[idiopathic thrombocytopenic purpura]].<ref name="pmid14782741"/> Autoimmune hemolytic anemia is a condition in which the red blood cells that normally carry [[oxygen]] and [[carbon dioxide]] are destroyed by an autoimmune process. Idiopathic thrombocytopenic purpura is a condition in which platelets are destroyed by an autoimmune process. Platelets are a component of blood that contribute to the formation of [[blood clot]]s in the body to prevent bleeding.

The syndrome was first described in 1951 by R. S. Evans and colleagues.<ref name="pmid14782741"/>

==Epidemiology==
<!-- see eMedicine article - need extract out primary sources for information -->

{{Empty section|date=July 2010}}

==Signs and symptoms==
It has been variously reported that between 10%<ref>{{GPnotebook|-919273445|Evan's syndrome}}</ref> and 23%<ref name="pmid2632179">{{cite journal |author=Cai JR, Yu QZ, Zhang FQ |title=[Autoimmune hemolytic anemia: clinical analysis of 100 cases] |language=Chinese |journal=Zhonghua Nei Ke Za Zhi |volume=28 |issue=11 |pages=670–3, 701–2 |year=1989 |pmid=2632179 |doi=}}</ref> of patients who have [[autoimmune hemolytic anemia]], will also have thrombocytopenia and thus Evans syndrome. The two features may occur together or sequentially.<ref name="pmid1451398">{{cite journal |author=Ng SC |title=Evans syndrome: a report on 12 patients |journal=Clinical and laboratory haematology |volume=14 |issue=3 |pages=189–93 |year=1992 |pmid=1451398 |doi=10.1111/j.1365-2257.1992.tb00364.x}}</ref>

==Causes==
Although Evans syndrome seems to be a disorder of immune regulation, the exact pathophysiology is unknown. Autoantibodies targeted at different antigenic determinants on red cells and platelets are assumed to cause isolated episodes of hemolytic anemia and thrombocytopenia, respectively. <ref>{{cite web|title=EVANS SYNDROME|url=http://emedicine.medscape.com/article/955266-overview#showall}}</ref>

==Diagnosis==
The diagnosis is made upon blood tests to confirm not only hemolytic anemia and idiopathic thrombocytopenic purpura, but also a positive [[Coombs test|direct antiglobulin test]] (DAT) and an absence of any known underlying etiology.<ref name="pmid16398647"/>

Other antibodies may occur directed against neutrophils and lymphocytes,<ref name="pmid7104228">{{cite journal |author=Pegels JG, Helmerhorst FM, van Leeuwen EF, van de Plas-van Dalen C, Engelfriet CP, von dem Borne AE |title=The Evans syndrome: characterization of the responsible autoantibodies |journal=Br. J. Haematol. |volume=51 |issue=3 |pages=445–50 |year=1982 |pmid=7104228 |doi=10.1111/j.1365-2141.1982.tb02801.x}}</ref> and "immunopancytopenia" has been suggested as a better term for this syndrome.<ref name="pmid7191890">{{cite journal |author=Pui CH, Wilimas J, Wang W |title=Evans syndrome in childhood |journal=J. Pediatr. |volume=97 |issue=5 |pages=754–8 |year=1980 |pmid=7191890 |doi=10.1016/S0022-3476(80)80258-7}}</ref>

==Treatment==
Initial treatment is with [[glucocorticoid]] [[corticosteroid]]s or [[intravenous immunoglobulin]], a procedure that is also used in ITP cases.<ref name="pmid2438958">{{cite journal |author=Nuss R, Wang W |title=Intravenous gamma globulin for thrombocytopenia in children with Evans syndrome |journal=The American journal of pediatric hematology/oncology |volume=9 |issue=2 |pages=164–7 |year=1987 |pmid=2438958 |doi=10.1097/00043426-198722000-00012}}</ref><ref name="pmid1483999">{{cite journal |author=Mehta JB, Singhal SB, Mehta BC |title=Intravenous immunoglobulin therapy of idiopathic thrombocytopenia |journal=The Journal of the Association of Physicians of India |volume=40 |issue=5 |pages=340–2 |year=1992 |pmid=1483999 |doi=}}</ref>&nbsp; In children, good response to a short steroid course is achieved in approximately 80 percent of cases.<ref name="pmid12531800">{{cite journal |author=Zecca M |title=Rituximab for the treatment of refractory autoimmune hemolytic anemia in children |journal=Blood |volume=101 |issue=10 |pages=3857–61 |year=2003 |month=15 May |pmid=12531800 |doi=10.1182/blood-2002-11-3547 |url=http://bloodjournal.hematologylibrary.org/cgi/content/full/101/10/3857 |author-separator=, |author2=Nobili B |author3=Ramenghi U |display-authors=3 |last4=Perrotta |first4=S |last5=Amendola |first5=G |last6=Rosito |first6=P |last7=Jankovic |first7=M |last8=Pierani |first8=P |last9=De Stefano |first9=P}}</ref>&nbsp; Although the majority of cases initially respond well to treatment, relapses are not uncommon and [[immunosuppressive]] drugs (e.g. [[ciclosporin]],<ref name="pmid8639426">{{cite journal |author=Emilia G, Messora C, Longo G, Bertesi M |title=Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders |journal=Br. J. Haematol. |volume=93 |issue=2 |pages=341–4 |year=1996 |pmid=8639426 |doi=10.1046/j.1365-2141.1996.4871026.x}}</ref><ref name="pmid11855146">{{cite journal |author=Liu H, Shao Z, Jing L |title=[The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome] |language=Chinese |journal=Zhonghua Xue Ye Xue Za Zhi |volume=22 |issue=11 |pages=581–3 |year=2001 |pmid=11855146 |doi=}}</ref> [[mycophenolate mofetil]], [[vincristine]]<ref name="pmid1404865">{{cite journal |author=Yokoyama K |title=[Thrombotic thrombocytopenic purpura achieving complete remission by slow infusion of vincristine] |language=Japanese |journal=Rinsho Ketsueki |volume=33 |issue=8 |pages=1084–9 |year=1992 |pmid=1404865 |doi= |author-separator=, |author2=Kojima M |author3=Komatsumoto S |display-authors=3 |last4=Nara |first4=M |last5=Nakano |first5=M |last6=Ikeda |first6=Y |last7=Toyama |first7=K}}</ref> and [[danazol]]<ref name="pmid8492411">{{cite journal |author=Koike M |title=[Effective danazol therapy for a patient with Evans syndrome] |language=Japanese |journal=Rinsho Ketsueki |volume=34 |issue=2 |pages=143–6 |year=1993 |pmid=8492411 |doi= |author-separator=, |author2=Ishiyama T |author3=Saito K |display-authors=3 |last4=Osawa |first4=H |last5=Hashimoto |first5=M |last6=Wakabayashi |first6=Y |last7=Tsuruoka |first7=N}}</ref>) are subsequently used,<ref name="pmid16398647"/> or combinations of these.<ref name="pmid7583383">{{cite journal |author=Scaradavou A, Bussel J |title=Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol |journal=J. Pediatr. Hematol. Oncol. |volume=17 |issue=4 |pages=290–5 |year=1995 |pmid=7583383 |doi=10.1097/00043426-199511000-00003}}</ref>

The [[off-label]] use of [[rituximab]] (trade name Rituxan) has produced some good results in acute and refractory cases,<ref name="pmid12531800"/><ref>{{cite journal |author=Shanafelt TD, Madueme HL, Wolf RC, Tefferi A |title=Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome |journal=Mayo Clin. Proc. |volume=78 |issue=11 |pages=1340–6 |year=2003 |month=November |pmid=14601692 |doi= 10.4065/78.11.1340|url=http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf |format=PDF}}</ref> although further relapse may occur within a year.<ref name="pmid16398647"/>&nbsp; [[Splenectomy]] is effective in some cases,<ref name="pmid16124452">{{cite journal |author=Hamidah A, Thambidorai CR, Jamal R |title=Prolonged remission after splenectomy for refractory Evans syndrome--a case report and literature review |journal=Southeast Asian J. Trop. Med. Public Health |volume=36 |issue=3 |pages=762–4 |year=2005 |pmid=16124452 |doi=}}</ref> but relapses are not uncommon.<ref name="pmid9329465">{{cite journal |author=Mathew P, Chen G, Wang W |title=Evans syndrome: results of a national survey |journal=J. Pediatr. Hematol. Oncol. |volume=19 |issue=5 |pages=433–7 |year=1997 |pmid=9329465 |doi=10.1097/00043426-199709000-00005}}</ref>

The only prospect for a permanent cure is the high-risk option of an allogeneic hematopoietic [[stem cell transplantation]] (SCT).<ref name="pmid9313889">{{cite journal |author=Martino R, Sureda A, Brunet S |title=Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome: a cautionary case report |journal=Bone Marrow Transplant. |volume=20 |issue=6 |pages=521 |year=1997 |pmid=9313889 |doi=10.1038/sj.bmt.1700924 |url=http://www.nature.com/bmt/journal/v20/n6/pdf/1700924a.pdf |format=PDF}}</ref><ref name="pmid11781654">{{cite journal |author=Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK |title=Allogeneic stem cell transplantation for Evans syndrome |journal=Bone Marrow Transplant. |volume=28 |issue=9 |pages=903–5 |year=2001 |pmid=11781654 |doi=10.1038/sj.bmt.1703237 |url=http://www.nature.com/bmt/journal/v28/n9/full/1703237a.html}}</ref>

==Prognosis==
Evan's syndrome is rare, serious, and has a reported mortality rate of 7%.{{Citation needed|date=September 2007}}<!-- thi svakue from eMedicine article, but we should cite primary source for this -->

It has been observed that there is a risk of developing other autoimmune problems and [[hypogammaglobulinemia]],<ref name="pmid3071168">{{cite journal |author=Wang WC |title=Evans syndrome in childhood: pathophysiology, clinical course, and treatment |journal=The American journal of pediatric hematology/oncology |volume=10 |issue=4 |pages=330–8 |year=1988 |pmid=3071168 |doi=10.1097/00043426-198824000-00013}}</ref> with recent research finding that 58% of children with Evans syndrome have CD4-/CD8- [[T cells]] which is a strong predictor for having [[autoimmune lymphoproliferative syndrome]].<ref name="pmid15542578">{{cite journal |author=Teachey DT |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |journal=Blood |volume=105 |issue=6 |pages=2443–8 |year=2005 |pmid=15542578 |doi=10.1182/blood-2004-09-3542 |url=http://bloodjournal.hematologylibrary.org/cgi/content/full/105/6/2443 |author-separator=, |author2=Manno CS |author3=Axsom KM |display-authors=3 |last4=Andrews |first4=T |last5=Choi |first5=JK |last6=Greenbaum |first6=BH |last7=McMann |first7=JM |last8=Sullivan |first8=KE |last9=Travis |first9=SF}}</ref>

==References==
{{reflist|2}}

{{Hematology}}

[[Category:Coagulopathies]]